224 related articles for article (PubMed ID: 11043569)
1. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity.
Mahata SK; Mahata M; Wakade AR; O'Connor DT
Mol Endocrinol; 2000 Oct; 14(10):1525-35. PubMed ID: 11043569
[TBL] [Abstract][Full Text] [Related]
2. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.
Mahata SK; O'Connor DT; Mahata M; Yoo SH; Taupenot L; Wu H; Gill BM; Parmer RJ
J Clin Invest; 1997 Sep; 100(6):1623-33. PubMed ID: 9294131
[TBL] [Abstract][Full Text] [Related]
3. Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A.
Preece NE; Nguyen M; Mahata M; Mahata SK; Mahapatra NR; Tsigelny I; O'Connor DT
Regul Pept; 2004 Apr; 118(1-2):75-87. PubMed ID: 14759560
[TBL] [Abstract][Full Text] [Related]
4. The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses.
Mahata SK; Mahata M; Wen G; Wong WB; Mahapatra NR; Hamilton BA; O'Connor DT
Mol Pharmacol; 2004 Nov; 66(5):1180-91. PubMed ID: 15326220
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a beta-strand/loop/beta-strand structure secured by hydrophobic interactions and predictive of activity.
Tsigelny I; Mahata SK; Taupenot L; Preece NE; Mahata M; Khan I; Parmer RJ; O'Connor DT
Regul Pept; 1998 Oct; 77(1-3):43-53. PubMed ID: 9809795
[TBL] [Abstract][Full Text] [Related]
6. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance.
Mahata SK; Mahata M; Parmer RJ; O'Connor DT
J Biol Chem; 1999 Jan; 274(5):2920-8. PubMed ID: 9915830
[TBL] [Abstract][Full Text] [Related]
7. The novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364). Properties and function.
Mahata SK; Mahata M; Livsey Taylor CV; Taupenot L; Parmer RJ; O'Connor DT
Adv Exp Med Biol; 2000; 482():263-77. PubMed ID: 11192587
[No Abstract] [Full Text] [Related]
8. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters.
Mahapatra NR; Mahata M; Mahata SK; O'Connor DT
J Hypertens; 2006 May; 24(5):895-904. PubMed ID: 16612252
[TBL] [Abstract][Full Text] [Related]
9. Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin.
Mahata SK; Mahapatra NR; Mahata M; Wang TC; Kennedy BP; Ziegler MG; O'Connor DT
J Biol Chem; 2003 Aug; 278(34):32058-67. PubMed ID: 12799369
[TBL] [Abstract][Full Text] [Related]
10. Interaction of the catecholamine release-inhibitory peptide catestatin (human chromogranin A(352-372)) with the chromaffin cell surface and Torpedo electroplax: implications for nicotinic cholinergic antagonism.
Taupenot L; Mahata SK; Mahata M; Parmer RJ; O'Connor DT
Regul Pept; 2000 Nov; 95(1-3):9-17. PubMed ID: 11062327
[TBL] [Abstract][Full Text] [Related]
11. Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells.
Lee JC; Taylor CV; Gaucher SP; Toneff T; Taupenot L; Yasothornsrikul S; Mahata SK; Sei C; Parmer RJ; Neveu JM; Lane WS; Gibson BW; O'Connor DT; Hook VY
Biochemistry; 2003 Jun; 42(23):6938-46. PubMed ID: 12795588
[TBL] [Abstract][Full Text] [Related]
12. New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A.
Briolat J; Wu SD; Mahata SK; Gonthier B; Bagnard D; Chasserot-Golaz S; Helle KB; Aunis D; Metz-Boutigue MH
Cell Mol Life Sci; 2005 Feb; 62(3):377-85. PubMed ID: 15723172
[TBL] [Abstract][Full Text] [Related]
13. A novel, catecholamine release-inhibitory peptide from chromogranin A: autocrine control of nicotinic cholinergic-stimulated exocytosis.
Mahata SK; Mahata M; Yoo SH; Taupenot L; Wu H; Aroda VR; Livsey CV; Taulane JP; Goodman M; Parmer RJ; O'Connor DT
Adv Pharmacol; 1998; 42():260-4. PubMed ID: 9327894
[No Abstract] [Full Text] [Related]
14. Molecular interactions of the physiological anti-hypertensive peptide catestatin with the neuronal nicotinic acetylcholine receptor.
Sahu BS; Mohan J; Sahu G; Singh PK; Sonawane PJ; Sasi BK; Allu PK; Maji SK; Bera AK; Senapati S; Mahapatra NR
J Cell Sci; 2012 May; 125(Pt 9):2323-37. PubMed ID: 22357947
[TBL] [Abstract][Full Text] [Related]
15. Catestatin regulates vesicular quanta through modulation of cholinergic and peptidergic (PACAPergic) stimulation in PC12 cells.
Sahu BS; Mahata S; Bandyopadhyay K; Mahata M; Avolio E; Pasqua T; Sahu C; Bandyopadhyay GK; Bartolomucci A; Webster NJG; Van Den Bogaart G; Fischer-Colbrie R; Corti A; Eiden LE; Mahata SK
Cell Tissue Res; 2019 Apr; 376(1):51-70. PubMed ID: 30467710
[TBL] [Abstract][Full Text] [Related]
16. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules.
Taylor CV; Taupenot L; Mahata SK; Mahata M; Wu H; Yasothornsrikul S; Toneff T; Caporale C; Jiang Q; Parmer RJ; Hook VY; O'Connor DT
J Biol Chem; 2000 Jul; 275(30):22905-15. PubMed ID: 10781584
[TBL] [Abstract][Full Text] [Related]
17. Proadrenomedullin N-terminal 20 peptide: minimal active region to regulate nicotinic receptors.
Mahata M; Mahata SK; Parmer RJ; O'Connor DT
Hypertension; 1998 Nov; 32(5):907-16. PubMed ID: 9822452
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo.
Kennedy BP; Mahata SK; O'Connor DT; Ziegler MG
Peptides; 1998; 19(7):1241-8. PubMed ID: 9786174
[TBL] [Abstract][Full Text] [Related]
19. Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure.
Mahapatra NR
Cardiovasc Res; 2008 Dec; 80(3):330-8. PubMed ID: 18541522
[TBL] [Abstract][Full Text] [Related]
20. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension.
Rao F; Wen G; Gayen JR; Das M; Vaingankar SM; Rana BK; Mahata M; Kennedy BP; Salem RM; Stridsberg M; Abel K; Smith DW; Eskin E; Schork NJ; Hamilton BA; Ziegler MG; Mahata SK; O'Connor DT
Circulation; 2007 May; 115(17):2271-81. PubMed ID: 17438154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
